Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Qian Li, Jingjing Han, Yonglin Yang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 112

Showing 1-25 of 112 citing articles:

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
Jiawen Cui, Yao Li, Yang Yang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116203-116203
Open Access | Times Cited: 36
Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
Xiaoting Luo, Xin He, Xingmei Zhang, et al.
MedComm (2024) Vol. 5, Iss. 2
Open Access | Times Cited: 30
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Jiaojiao Zheng, Siying Wang, Lei Xia, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 4
Reprogramming of Treg cells in the inflammatory microenvironment during immunotherapy: a literature review
Xinyan Wu, Zhigang Zhou, Qiang Cao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 31
Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response
Mason Webb, Thanich Sangsuwannukul, Jacob P. van Vloten, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 10
Immune Checkpoints and the Immunology of Liver Fibrosis
Ioannis Tsomidis, Argyro Voumvouraki, Elias Kouroumalis
Livers (2025) Vol. 5, Iss. 1, pp. 5-5
Open Access | Times Cited: 1
Effect of external beam radiation therapy versus transcatheter arterial chemoembolization for non-diffuse hepatocellular carcinoma (≥ 5 cm): a multicenter experience over a ten-year period
Ke Su, Fei Wang, Xueting Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 19
Mechanism of M2 type macrophage-derived extracellular vesicles regulating PD-L1 expression via the MISP/IQGAP1 axis in hepatocellular carcinoma immunotherapy resistance
Xiaobo Wang, Xuxing Ye, Yanping Chen, et al.
International Immunopharmacology (2023) Vol. 124, pp. 110848-110848
Closed Access | Times Cited: 18
The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma
Nicolò Brandi, Matteo Renzulli
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8598-8598
Open Access | Times Cited: 17
Emerging Trends in Gastrointestinal Cancer Targeted Therapies: Harnessing Tumor Microenvironment, Immune Factors, and Metabolomics Insights
Sanchita Rauth, Mokenge P. Malafa, Moorthy P. Ponnusamy, et al.
Gastroenterology (2024) Vol. 167, Iss. 5, pp. 867-884
Closed Access | Times Cited: 7
Bio-responsive Au-miR-183 inhibitor enhances immunotherapy in hepatocellular carcinoma by inducing immunogenic cell death
Liang Yin, Yu Wei, Ya Liu, et al.
Journal of Controlled Release (2024) Vol. 368, pp. 498-517
Open Access | Times Cited: 6
WTAP‐induced N6‐methyladenosine of PD‐L1 blocked T‐cell‐mediated antitumor activity under hypoxia in colorectal cancer
Qizhi Liu, Nan Zhang, Junyi Chen, et al.
Cancer Science (2024) Vol. 115, Iss. 6, pp. 1749-1762
Open Access | Times Cited: 6
BCG as an Innovative Option for HCC Treatment: Repurposing and Mechanistic Insights
Farzam Vaziri, Tahereh Setayesh, Ying Hu, et al.
Advanced Science (2024) Vol. 11, Iss. 14
Open Access | Times Cited: 5
A Novel Bispecific Antibody CVL006 Superior to AK112 for Dual Targeting of PD-L1 and VEGF in Cancer Therapy
Hao Huang, Xiaokun Shen
(2025)
Open Access
ENTPD8 Overexpression Enhances Anti-PD-L1 Therapy in Hepatocellular Carcinoma via miR-214-5p Inhibition
Siqi Zhao, Minjie Chen, Fei Chen, et al.
iScience (2025) Vol. 28, Iss. 2, pp. 111819-111819
Open Access
Application of multi-omics in hepatocellular carcinoma: new prospects for classification and precise diagnosis and treatment
Jiaxue He, Xintong Hu, Liguo Chen, et al.
Hepatoma Research (2025)
Open Access
CXCR4 antagonist-loaded nanoparticles reprogram the tumor microenvironment and enhance immunotherapy in hepatocellular carcinoma
Sheng‐Liang Cheng, Chien-Huang Wu, Yun‐Jen Tsai, et al.
Journal of Controlled Release (2025) Vol. 379, pp. 967-981
Closed Access
Antitumor Research Based on Drug Delivery Carriers: Reversing the Polarization of Tumor-Associated Macrophages
Xinyu Cao, Shen Wan, Bingyu Wu, et al.
Molecular Pharmaceutics (2025)
Closed Access
Phase separation of EEF1E1 promotes tumor stemness via PTEN/AKT-mediated DNA repair in hepatocellular carcinoma
Xiaofan Pu, Chaolei Zhang, Junbin Jin, et al.
Cancer Letters (2025), pp. 217508-217508
Closed Access
Advances in Ultrasound-Targeted Microbubble Destruction (UTMD) for Breast Cancer Therapy
Yunfeng Wu, Yu-xi Liu, Han Wu, et al.
International Journal of Nanomedicine (2025) Vol. Volume 20, pp. 1425-1442
Open Access
Enhanced effect of radiofrequency ablation on HCC by siRNA-PD-L1-endostatin Co-expression plasmid delivered
Pengfei Chen, Kun Li, Jinwei Chen, et al.
Translational Oncology (2025) Vol. 53, pp. 102319-102319
Open Access
NK cell‐based immunotherapy for hepatocellular carcinoma: Challenges and opportunities
Pei Guo, Liyuan Zhong, Tao Wang, et al.
Scandinavian Journal of Immunology (2025) Vol. 101, Iss. 2
Closed Access
Clinical characteristics and unique presentations of immune checkpoint inhibitor induced type 1 diabetes in Chinese patients from a single institution
Wei Liu, Chunmei Li, Yayu Fang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Systemic management of advanced HCC: an increasingly complex game
A. Martirena, P. Lombardi, David J. Pinato, et al.
ESMO Gastrointestinal Oncology (2025) Vol. 7, pp. 100139-100139
Open Access
Antibody-Targeted Bismuth Gadolinium Nanoconjugate for Image-Guided Radiotherapy of Hepatocellular Carcinoma
Archana Mishra, Erin Marie D. San Valentin, Allan John R. Barcena, et al.
ACS Applied Materials & Interfaces (2025)
Closed Access
Page 1 - Next Page

Scroll to top